Sensus Healthcare (NASDAQ:SRTS) Share Price Crosses Below Fifty Day Moving Average – What’s Next?

Sensus Healthcare, Inc. (NASDAQ:SRTS)’s stock price passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $3.10 and traded as low as $3.10. Sensus Healthcare shares last traded at $3.15, with a volume of 8,164 shares traded.

Analysts Set New Price Targets

Several equities research analysts have commented on SRTS shares. Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Alliance Global Partners reiterated a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Finally, Lake Street Capital decreased their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Sensus Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $5.83.

Sensus Healthcare Trading Up 1.0%

The stock has a market cap of $51.85 million, a PE ratio of -3.35 and a beta of 1.13. The business has a 50-day moving average price of $3.10 and a 200-day moving average price of $3.45.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41). The company had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $4.60 million. Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.

Insiders Place Their Bets

In other news, Director Eric Sachetta acquired 37,537 shares of the stock in a transaction that occurred on Friday, August 28th. The shares were bought at an average cost of $3.44 per share, for a total transaction of $129,127.28. Following the acquisition, the director owned 267,480 shares in the company, valued at approximately $920,131.20. This represents a 16.32% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have bought 120,171 shares of company stock valued at $405,230. Company insiders own 10.20% of the company’s stock.

Institutional Trading of Sensus Healthcare

Several large investors have recently made changes to their positions in SRTS. State Street Corp grew its holdings in Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after buying an additional 3,400 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock valued at $730,000 after purchasing an additional 3,766 shares during the period. EP Wealth Advisors LLC purchased a new position in Sensus Healthcare during the second quarter worth about $49,000. XTX Topco Ltd acquired a new position in Sensus Healthcare in the 4th quarter valued at about $77,000. Finally, Jane Street Group LLC purchased a new stake in shares of Sensus Healthcare in the 4th quarter valued at approximately $79,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.